 WALTHAM, Mass., March 31, 2021 PRNewswire -- Syndax Pharmaceuticals, Inc. Syndax, the Company or we Nasdaq: SNDX, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with chronic graft versus host disease cGVHD. 